Chilton Investment Company’s Myriad Genetics MYGN Stock Holding History

Chilton Investment Company’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-290,690	Closed	-$4.85M	–	142
2016 Q4	$4.85M	Buy	290,690 +185,616	+177%	+$3.36M	0.2%	54
2016 Q3	$2.16M	Buy	105,074 +63,961	+156%	+$1.62M	0.08%	66
2016 Q2	$1.26M	Buy	+41,113	New	+$1.43M	0.04%	90

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Chilton Investment Company's MYGN Position: Q1 2017 in Review

Chilton Investment Company sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 290,690 shares — an estimated $4.85M sold.

Chilton Investment Company first reported a position in MYGN in Q2 2016 and held it in 3 quarters. The position peaked at $4.85M in Q4 2016. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

Chilton Investment Company reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
Chilton Investment Company sold 290,690 Myriad Genetics shares in Q1 2017, an estimated $4.85M.
Chilton Investment Company first reported a position in Myriad Genetics in Q2 2016 and held it in 3 quarters.
Chilton Investment Company's Myriad Genetics position peaked at $4.85M in Q4 2016.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on Chilton Investment Company's 13F filing for Q1 2017, filed 15 May 2017.